- Home
- NDSN vs BMRN Comparison
NDSN vs BMRN Comparison
Compare NDSN & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NDSN
- BMRN
- Stock Information
- Founded
- NDSN 1935
- BMRN 1996
- Country
- NDSN United States
- BMRN United States
- Employees
- NDSN N/A
- BMRN N/A
- Industry
- NDSN Industrial Machinery/Components
- BMRN Biotechnology: Pharmaceutical Preparations
- Sector
- NDSN Industrials
- BMRN Health Care
- Exchange
- NDSN Nasdaq
- BMRN Nasdaq
- Market Cap
- NDSN 12.0B
- BMRN 13.7B
- IPO Year
- NDSN N/A
- BMRN 1999
- Fundamental
- Price
- NDSN $180.81
- BMRN $59.17
- Analyst Decision
- NDSN Strong Buy
- BMRN Buy
- Analyst Count
- NDSN 5
- BMRN 22
- Target Price
- NDSN $256.40
- BMRN $94.00
- AVG Volume (30 Days)
- NDSN 454.8K
- BMRN 2.0M
- Earning Date
- NDSN 05-19-2025
- BMRN 05-01-2025
- Dividend Yield
- NDSN 1.73%
- BMRN N/A
- EPS Growth
- NDSN N/A
- BMRN 153.71
- EPS
- NDSN 7.86
- BMRN 2.21
- Revenue
- NDSN $2,672,148,000.00
- BMRN $2,853,915,000.00
- Revenue This Year
- NDSN $5.02
- BMRN $12.23
- Revenue Next Year
- NDSN $4.88
- BMRN $9.93
- P/E Ratio
- NDSN $23.00
- BMRN $26.81
- Revenue Growth
- NDSN 0.79
- BMRN 17.97
- 52 Week Low
- NDSN $165.03
- BMRN $52.93
- 52 Week High
- NDSN $279.38
- BMRN $94.85
- Technical
- Relative Strength Index (RSI)
- NDSN 38.95
- BMRN 37.64
- Support Level
- NDSN $178.93
- BMRN $52.93
- Resistance Level
- NDSN $187.84
- BMRN $60.93
- Average True Range (ATR)
- NDSN 8.17
- BMRN 3.18
- MACD
- NDSN -0.13
- BMRN -0.53
- Stochastic Oscillator
- NDSN 40.80
- BMRN 34.01
About NDSN Nordson Corporation
Nordson manufactures equipment (including pumps, valves, dispensers, applicators, filters, and pelletizers) used for dispensing adhesives, coatings, sealants, and other materials. The firm serves a diverse range of end markets including packaging, medical, electronics, and industrial. Nordson's business is organized into three segments: industrial precision solutions, medical and fluid solutions, and advanced technology solutions. The company generated approximately $2.7 billion in revenue in its fiscal 2024.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.